COMMUNIQUÉS West-GlobeNewswire

Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
10/03/2026
Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, Switzerland – March [...]
Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
10/03/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total Medical Device sales rose by [...]
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
10/03/2026
Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy [...]
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
10/03/2026
Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective [...]
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
10/03/2026
Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will [...]
Press Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test
10/03/2026
PRESS RELEASE 10/03/2025, 08:00 CET Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test Idylla™ CDx MSI Test is the Second Fully Automated Companion Diagnostic Test Approval for Biocartis under [...]
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
10/03/2026
$12 Million of Tranche Warrants Potential Financing Within One Year From Closing SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
09/03/2026
CRANFORD, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
The Right to Religious Exemption to Vaccination Upheld in Court, according to the Journal of American Physicians and Surgeons
09/03/2026
TUCSON, Ariz., March 09, 2026 (GLOBE NEWSWIRE) -- Despite concerns about COVID vaccines, vaccine mandates are increasing in hospitals, schools, military service, and even ordinary employment, writes Andrew Schlafly in [...]
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
09/03/2026
– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year [...]
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
09/03/2026
Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development [...]
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
09/03/2026
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two [...]
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
09/03/2026
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and [...]
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
09/03/2026
Anniversary Milestone Highlights Expanded Manufacturing Capacity, Stronger Asia-Pacific Presence, and Measurable Contributions to Global Supply Chain Resilience FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One [...]
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
09/03/2026
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution [...]
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
09/03/2026
– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with [...]
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
09/03/2026
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment WALTHAM, Mass., March 09 [...]
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
LifeMD Reports Fourth Quarter and Full Year 2025 Results
09/03/2026
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral [...]

Pages